loading page

Off-label drug use in Neonatal Intensive Care Units in China: a descriptive, multicenter study
  • +10
  • Meng Lv,
  • Yan Li,
  • Chong Sun,
  • Yuxue Zhou,
  • Shirong Peng,
  • Qingsheng Liu,
  • Li Li,
  • Hongli Chen,
  • Xinsheng Wei,
  • Kaili Li,
  • Zhaohui Li,
  • Wei Hu,
  • Qing Xu
Meng Lv
Children’s Hospital Affiliated to Zhengzhou University

Corresponding Author:[email protected]

Author Profile
Yan Li
Children’s Hospital Affiliated to Zhengzhou University
Author Profile
Chong Sun
Children’s Hospital Affiliated to Zhengzhou University
Author Profile
Yuxue Zhou
Children’s Hospital Affiliated to Zhengzhou University
Author Profile
Shirong Peng
Children’s Hospital Affiliated to Zhengzhou University
Author Profile
Qingsheng Liu
Jiaozuo Maternal and Child Health Care Hospital
Author Profile
Li Li
Luoyang Maternal and Child Health Care Hospital
Author Profile
Hongli Chen
Xinxiang Central Hospital
Author Profile
Xinsheng Wei
Yuzhou City People's Hospital
Author Profile
Kaili Li
Zhecheng People's Hospital
Author Profile
Zhaohui Li
Children’s Hospital Affiliated to Zhengzhou University
Author Profile
Wei Hu
Xinyang Central Hospital
Author Profile
Qing Xu
Lankao First People's Hospital
Author Profile

Abstract

Abstract Aim: Off-label drug use in neonates remains a global problem. The retrospective, multicenter study was to study the rates and reasons of off-label drug use among representative NICUs in Henan, China. Methods: Prescriptions were randomized sampled from eight NICUs. Patient characteristics and diseases were collected. Classifications of off-label drug use including age, frequency, dose, indication and route of administration were analyzed. Results: 1770 neonates sampled from eight NICUs were evaluable in the study, with a mean body weight 2.98 kg (SD = 0.80, range 0.78-6.0), 92.03% of whom were exposed to ≥ 1 off-label prescription. 5813 prescriptions with 113 drugs were registered, 84.62% of which were off label. 63.03% of the off-label use was in relation to age. Conclusion: Off-label drug use among neonates remains fairly prevalent in Henan, China. Initiative and effective implementation is urgently required to improve this situation.